UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Metabolic reprogramming in clear cell renal cell carcinoma

Nature reviews. Nephrology, 2017-07, Vol.13 (7), p.410-419

2017

Volltextzugriff (PDF)

A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial

The Lancet (British edition), 2021-02, Vol.397 (10275), p.695-703

2021

Volltextzugriff (PDF)

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer

Cell, 2018-07, Vol.174 (3), p.758-769.e9

2018

Volltextzugriff (PDF)

Aurora Kinases as Anticancer Drug Targets

Clinical cancer research, 2008-03, Vol.14 (6), p.1639-1648

2008

Volltextzugriff (PDF)

Squamous cell lung cancer: from tumor genomics to cancer therapeutics

Clinical cancer research, 2015-05, Vol.21 (10), p.2236-2243

2015

Volltextzugriff (PDF)

Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer

Oncogene, 2023-02, Vol.42 (9), p.693-707

2023

Volltextzugriff (PDF)

Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC

Journal of thoracic oncology, 2018-10, Vol.13 (10), p.1560-1568

2018

Volltextzugriff (PDF)

Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial

Journal of clinical oncology, 2013-02, Vol.31 (4), p.412-419

2013

Volltextzugriff (PDF)

Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

Journal of the National Comprehensive Cancer Network, 2022-01, Vol.20 (1), p.71-90

2022

Volltextzugriff (PDF)

Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer

Journal of clinical oncology, 2011-08, Vol.29 (22), p.2965-2971

2011

Volltextzugriff (PDF)

A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma

Investigational new drugs, 2014-02, Vol.32 (1), p.178-187

2014

Volltextzugriff (PDF)

Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124

Journal of clinical oncology, 2009-05, Vol.27 (15), p.2530-2535

2009

Volltextzugriff (PDF)

Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel

European urology, 2024-02, Vol.85 (2), p.171-176

2024

Volltextzugriff (PDF)

Trastuzumab, Paclitaxel, Carboplatin, and Gemcitabine in Advanced Human Epidermal Growth Factor Receptor-2/neu–Positive Urothelial Carcinoma: Results of a Multicenter Phase II National Cancer Institute Trial

Journal of clinical oncology, 2007-06, Vol.25 (16), p.2218-2224

2007

Volltextzugriff (PDF)

Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial

The Lancet (British edition), 2023-09, Vol.402 (10407), p.1043-1051

2023

Volltextzugriff (PDF)

First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors

Clinical cancer research, 2019-11, Vol.25 (21), p.6309-6319

2019

Volltextzugriff (PDF)

RORγ is a targetable master regulator of cholesterol biosynthesis in a cancer subtype

Nature communications, 2019-10, Vol.10 (1), p.4621-17, Article 4621

2019

Volltextzugriff (PDF)

Disease Control Rate at 8 Weeks Predicts Clinical Benefit in Advanced Non–Small-Cell Lung Cancer: Results From Southwest Oncology Group Randomized Trials

Journal of clinical oncology, 2008-01, Vol.26 (3), p.463-467

2008

Volltextzugriff (PDF)

Japanese-US Common-Arm Analysis of Paclitaxel Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Model for Assessing Population-Related Pharmacogenomics

Journal of clinical oncology, 2009-07, Vol.27 (21), p.3540-3546

2009

Volltextzugriff (PDF)

Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial

The lancet oncology, 2013-08, Vol.14 (9), p.893-900

2013

Volltextzugriff (PDF)

Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

The New England journal of medicine, 2004-10, Vol.351 (15), p.1513-1520

2004

Volltextzugriff (PDF)

Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer

Scientific reports, 2021-03, Vol.11 (1), p.6377-6377, Article 6377

2021

Volltextzugriff (PDF)

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer

Cell, 2018-10, Vol.175 (3), p.889-889

2018

Volltextzugriff (PDF)

A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)

BMC cancer, 2024-07, Vol.23 (Suppl 1), p.1-12, Article 1253

2024

Volltextzugriff (PDF)

1 – 25 von 440

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(428)
Mit Volltextzugriff
(387)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(257)
Life Sciences & Biomedicine
(255)
Humans
(227)
Oncology
(207)
Male
(145)
Middle Aged
(114)
Aged
(111)
Female
(94)
Adult
(77)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(75)
Biological And Medical Sciences
(75)
Medical Sciences
(75)
Lung Neoplasms - Drug Therapy
(74)
Aged, 80 And Over
(73)
Carcinoma, Non-Small-Cell Lung - Drug Therapy
(58)
Treatment Outcome
(53)
Tumors
(51)
Urology & Nephrology
(48)
Antineoplastic Agents - Therapeutic Use
(40)
Lung Neoplasms - Pathology
(40)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(11)

Menü

Weitere Dienste

Einstellungen

Metabolic reprogramming in clear cell renal cell carcinoma

A comparison of sunitinib with cabozantinib, crizotinib, and savolitinib for treatment of advanced papillary renal cell carcinoma: a randomised, open-label, phase 2 trial

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer

Aurora Kinases as Anticancer Drug Targets

Squamous cell lung cancer: from tumor genomics to cancer therapeutics

Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer

Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC

Cabozantinib in Patients With Advanced Prostate Cancer: Results of a Phase II Randomized Discontinuation Trial

Kidney Cancer, Version 3.2022, NCCN Clinical Practice Guidelines in Oncology

Randomized Phase III Placebo-Controlled Trial of Carboplatin and Paclitaxel With or Without the Vascular Disrupting Agent Vadimezan (ASA404) in Advanced Non–Small-Cell Lung Cancer

A phase II trial of AS1411 (a novel nucleolin-targeted DNA aptamer) in metastatic renal cell carcinoma

Phase III Trial of Irinotecan/Cisplatin Compared With Etoposide/Cisplatin in Extensive-Stage Small-Cell Lung Cancer: Clinical and Pharmacogenomic Results From SWOG S0124

Bone Biomarkers and Subsequent Survival in Men with Hormone-sensitive Prostate Cancer: Results from the SWOG S1216 Phase 3 Trial of Androgen Deprivation Therapy with or Without Orteronel

Trastuzumab, Paclitaxel, Carboplatin, and Gemcitabine in Advanced Human Epidermal Growth Factor Receptor-2/neu–Positive Urothelial Carcinoma: Results of a Multicenter Phase II National Cancer Institute Trial

Adjuvant everolimus after surgery for renal cell carcinoma (EVEREST): a double-blind, placebo-controlled, randomised, phase 3 trial

First-in-Human Study of Mivebresib (ABBV-075), an Oral Pan-Inhibitor of Bromodomain and Extra Terminal Proteins, in Patients with Relapsed/Refractory Solid Tumors

RORγ is a targetable master regulator of cholesterol biosynthesis in a cancer subtype

Disease Control Rate at 8 Weeks Predicts Clinical Benefit in Advanced Non–Small-Cell Lung Cancer: Results From Southwest Oncology Group Randomized Trials

Japanese-US Common-Arm Analysis of Paclitaxel Plus Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Model for Assessing Population-Related Pharmacogenomics

Docetaxel and atrasentan versus docetaxel and placebo for men with advanced castration-resistant prostate cancer (SWOG S0421): a randomised phase 3 trial

Docetaxel and Estramustine Compared with Mitoxantrone and Prednisone for Advanced Refractory Prostate Cancer

Phase Ib trial of reformulated niclosamide with abiraterone/prednisone in men with castration-resistant prostate cancer

Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer

A randomized, open-label, phase 3 trial of pembrolizumab plus epacadostat versus sunitinib or pazopanib as first-line treatment for metastatic renal cell carcinoma (KEYNOTE-679/ECHO-302)

Phase I Study of Cabozantinib and Nivolumab Alone or With Ipilimumab for Advanced or Metastatic Urothelial Carcinoma and Other Genitourinary Tumors

Suchergebnisse filtern